Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897 is registered in ClinicalTrials.gov with Innovation Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04784897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04784897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Lead sponsor
Innovation Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2021
Completion date
July 30, 2021
Enrollment
120 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19